AMPHAmphastar Pharmaceuticals, Inc.
Is the price fair?
Neither cheap nor expensive: nothing decisive, though modest expectations priced in.
Priced for a decline (~−8% a year). The price demands less than its three-year revenue growth of 11% a year, expectations look modest.
In its normal range: P/E 15.8 vs a 19.4 median over 33 quarters (−19% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What AMPH's price assumes
Amphastar Pharmaceuticals, Inc. trades at 15.8× earnings against 19.7× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.
Trailing P/E · Drug Manufacturers - Specialty & Generic median 19.7 · cheaper than the typical name in its group
- Free cash flow yield
- 13%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- −7.7%
Growth the price implies · The price pays for −7.7% free cash flow growth a year for a decade; the business has delivered +15% a year over the last three.
Details›
- Healthcare median P/E509 names
- 26.2
- Drug Manufacturers - Specialty & Generic median P/E45 names
- 19.7
- Free cash flow, trailing twelve months
- $153M
- Market capitalisation
- $1.14B
- 3-year revenue growth
- +11%
- 3-year free cash flow growth
- +15%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $23.89 |
| Its own P/E history, median | $32.85 |
| Its own P/E history, upper quartile | $72.86 |
| 52-week range | $16.87 – $29.40 |
| Today | $26.63 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, Specialty & Generic
Ranks #4 of 41 by RyuScore